Subject index - volume 33

SUBJECT INDEX

ADENOSINE regulation of lipolysis

-

VOLUME 33

831

ADRENERGIC RECEPTORS PGE production 17 ADRENOCORTICOTROPIN RELEASE adenohypophysis, rat 470 melittin 479 AGGREGATION LTB4 analogs

617

AIRWAY HYPERACTIVITY LTD4 209 PAF 209 AIRWAY OBSTRUCTION A23187 action 567 ALKALINE PHOSPHATE PGE 241 ute $. ine stromal cells

241

ANTIBODY-AFFINITY COLUMN gas chromatography-mass spectrometry thromboxane B2 149 ANTI-THROMBOTIC EFFECT hamster cheek pouch isocarbacyclin 161

149

161

ARACHIDONIC ACID METABOLISM effect of ethanol 579 effect of pyridoquinazoline thromboxane synthase inhibitor E. Coli endotoxemia, sheep 879 inhibition by eicosatetraenoic acid 12-keto-eicosatetraenoic acid 315 12-oxo-dodecatrienoic acid 315 platelets, human 315 ARRHYTHMIAS ouabain-induced PGE2, PGF2 , PG12

603

339 339

ASPIRIN effect on lung vascular permeability

431

87

ASSAY sulfidopeptide leukotriene BETA-ENDORPHIN RELEASE adenohypophysis, rat melittin 479

693

479

BINDING LTB4 845 LTB4 analogs 617, 855 PAF-acether 931 thromboxane A2/prostaglandin H2 agonist, U46619 BIOSYNTHESIS LTB4 539 BLOOD FLOW PGE2 analog, DHV-PGE2-ME BRONCHIECTASIS leukotrienes, sputum prostanoids, sputum CARDIOPROTECTION PG12, 7-oxo-PGI2

627 663 663

505

CELL PROLIFERATION aortic endothelial cell, bovine arterial smooth muscle, human fibroblasts, lung 903 LTB4, LTC 531 $03 PGE2 915 PG12 CERVIX aminiotomy 757 13,14-dihydro-15-keto-PGF2 CHRONIC BRONCHITIS leukotrienes, sputum prostanoids, sputum

531 915

757

663 663

COMPLEMENT mepacrine 287 thromboxane production, rabbit liver CONJUGATED OCTADECATRIENOIC ACIDS prostaglandin biosynthesis 403

287

789

CONTRACTILITY lipoxygenase metabolites myometrium, human a37 CONSTRICTION coronary arteries, cat synthetic thromboxane A2

a37

771 771

13,14-DIDEHYDRO-20-METHYL-CARBOPROSTACYCLIN aggregation, guinea pig platelets 351 blood pressure 351 central nervous system, mice 351 PG12 derivative 351 DIET essential fatty acid deficient I81 platelet-activating fctor iai thromboxane B2 production 181 slow-reacting substance factor 181 13,14-DIHYDRO-15-KETO-PGF2 aminiotomy 757 cervix 757 5-6-DIHYDRO-PGE activity 133 identification

137

E. COLI ENDOTOXEMIA arachidonic acid metabolism a79 pyridoquinazoline thromboxane synthase inhibition EICOSADIYNOIC ACID arachidonic acid metabolism

603

EPIGASTRIC ISLAND FLAP PGE /TXA2 balance 445 rab2, it 445 FUROSEMIDE plasma renin activity 275 thromboxane B PGI formation thromboxane s3' nthetg se inhibition

275

GAS CHROMATTOGRAPHY-MASS SPECTROMETRY antibody-affinity column 149 thromboxane B2 149

275

a79

GLUCOCORTICOID human proliferative phase endometrium

919

GLUTATHIONE MIXED DISULPHIDE INHIBITORS NADP-linked 15-hydroxyprostaglandin dehydrogenase placenta, human 383 GLUTATHIONE THIOSULFATE NADP-linked 15-hydroxyprostaglandin dehydrogenase placenta, human 391 5-HETE contractility, human myometrium

a37

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY sulfidopeptide leukotrienes, plasma HISTAMINE lung vascular permeability

693

431

HYPERTENSION DAHL salt-sensitive rats 727 727 PG12, thromboxane A2 HYPOXIA fetal placenta, human prostaglandin release

553 553

HYSTERECTOMY luteal progesterone production 561 effect of PGF2 561 PAF 931 interleukin-1 release and synthesis ISCHEMIA-INDUCED INJURY anti-inflammatory steroids 63 BW755C 63 leukocyte infiltration necrosis 63 ISOCARBACYCLIN anti-thrombotic activity lipid microspheres 161 6-KETO-PROSTAGLANDIN Fl A23187 stimulation 101 uterus, guinea pig 101

63

161

931

383

383

6-KETO-PROSTAGLANDIN Fl fetal placenta, human hypoxia 553

RELEASE 553

LEUKOTRIENE assay, HPLC, radioimmunoassay 693 biliary and urinary excretion 717 cysteinyl-containing 591 formation, human aterial tissues 591 metabolism, inhibition by L-serine borate 709 and glutathione 121 radioreceptor assay sputum, chronic bronchitis and/or bronchiectasis

analogs 617 539 biosynthesis bronchoconstriction 1 cell proliferation 531 contractility, human myometrium inhibition by nafazatrom 539 leukocyte aggregation and binding metabolism 807 neutrophil infiltration 1 PAF-induced aggregation 253 synergism with PGE2 799 LEUKOTRIENE C cell prolifer.4 tion 531 contraction, guinea pig trachea hypoxic pulmonary vasoconstriction 5-lipoxygenase inhibition 113

837 617

113 181

LEUKOTRIENE D airway hypera8 tivity 209 bronchus, guinea pig 199 contraction 113, 199, 209 excretion of electrolytes, dog kidney 5-lipoxygenase inhibitors 113 interaction with PGE 301 lung parenchyma, gui,&ea pig 199 PAF 209 LIPOLYSIS adenosine 831 regulation 831 prostaglandins 831 viprostol, anti-hypertensive PGE2 analog

301

767

663

5-LIPOXYGENASE inactivation by 5(s)-hydroperoxveicosatetraenoic acid kinetic studies asLIVER DAMAGE cc1 869 co18hicine vioprostil

a5

869 869

LUTEAL FUNCTION intrauterine iodine infusion, cycling goats LUNG VASCULAR PERMEABILITY effects of aspirin and histamine MASS SPECTROMETRY analysis of prostaglandins deuterium labelled methoxines

743

431

599 599

MELITTIN adenocorticotropin and beta-endoorphin release METABOLISM arachidonic acid leukotriene 709

479

579

MYOTROPIC ACTIVITY histamine 199 isolated pulmonary tissues, guinea pig LTD4 199 PAF 199

197

NADP-LINKED 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE glutathione mixed disulphide inhibitors 383, 391 placenta, human 383, 391 OCCLUSION REPERSION MODEL ischemia induced edema, rabbit ear necrosis, rabbit ear 63 7-0X0-PROSTACYCLIN cardioprotection

63

505

PLACENTA glutathione mixed disulphide inhibitors 383, 391 NADP-linked 15-hydroxyprostaglandin dehydrogenase

383, 391

PLANTS prostaglandins 363 prostaglandin-related compounds PLATELET binding, U46619 half-life, uptake PGI2 783

363

789 783

PAF-ACETHER antagonists 931 interleukin-1 release synthesis 931 PAF-ACETHER ANTAGONIST BN52021 265 bronchoconstriction passive anaphylaxis

931

265 265

PLATELET-ACTIVATING FACTOR aggregation 253 airway hyperactivity 209 bronchus, guinea pig 199 contractility 199 lung parenchyma, guinea pig 199 LTB4 253 LTD 209 tradhea, guinea pig 199, 209 relaxation 199 PHOSPHOLIPASE A2 ACTIVITY lamellar bodies, adult rabbit lung 639 subcellular fractions, adult rabbit lung PREGNANCY 16, 16-dimethyl-transserum relaxin 739

639

2-PGEI-methyl ester

PROGESTERONE PGF 561 hum& proliferative phase endometrium hysterectomy 561 PGE PGF uptake and release 51 ute 2' ine s8rips, ovariectomized rats

739

919 51

PROSTACYCLIN cardioprotection 505 centrai nervous system, cat 339 neuromodulator, svmpatheticallv stimulated rabbit heart _ _ ouabain-induced anti-arrhythmic effects 339 synthesis 3 vascular, DAHL salt sensitive rats 727

675

PROSTACYCLIN DERIVATIVE 13, 14-didehydro-20-methyl-carboprostacyclin (FCE 2217, FCE 22176) 351 PROSTACYCLIN/THROMBOXANE A2 BALANCE cutaneous microcirculation 445 epigastric island flap, rabbit 445 PROSTAGLANDIN BIOSYNTHESIS inhibition by conjugated octadecatrienoic acids PROSTAGLANDIN E A23187 stimulat3on 101 alkaline phosphate activity 241 central nervous system 339 excretion of electrolytes, dog kidney interaction with LTD _ -3Olouabain-induced anti!arrthvmic effects progesterone 51 synergism with LTB4 799 uptake and release 51 uterus, guinea pig 101

403

301 339

::;T:;$$c"&$;:;; 767 cutaneous blood flow 627 DHV-PGE2-ME (or CLll5,347) 627 gastric anti-secretory properties 169 16-phenoxy-omega-tetranor PGE 169 viprostol, anti-hypertensive &nalog 767 PROSTAGLANDIN E PRODUCTION activation of protein kinase C adrenergic receptors 17 granulosa cells, swine 819 vas deferens, rabbit 17 PROSTAGLANDIN E2 RELEASE fetal placenta, human 553 hypoxia

819

553

PROSTAGLANDIN F A23187 stimulat1on 101 central nervous system, cat 339 cyclic AMP 227 hysterectomy 561 intrauterine iodine infusion, cycling goats luteal cells, bovine 227 ouabain-induced anti-arrhythmic effect 339 progesterone production 51, 227, 561 uptake and release 51 uterus, guinea pig 101

743

PROSTAGLANDIN F2 RELEASE fetal placenta, human 553 hypoxia 553 11 -PROSTAGLANDIN F2 9 basal level, rat tissue radioimmunoassay 517

517

PROSTAGLANDIN-RELATED COMPOUNDS plants 363 PROSTAGLANDINS biliary, fecal and urinary excretion, rat gastrointestinal tract, rabbit 459 inhibition of synthesis 919 mass spectral analysis 599 plants 363 regulation of lipolysis 831 synthesis 459, 919

419

PROSTANOIDS sputum 663 PROSTANOID RELEASE airway cartilage, guinea pig 651 development of tone in smooth muscle, guinea pig PROTEIN KINASE C activation 819 PGEZ synthesis 819 PSORIASIS LTB4 metabolism

807

RADIOIMMUNOASSAY leukotrienes 539, 663, 693 9 11 -PGF2 517 proktanoids 663 RECEPTORS LTB4 855 LTB4 analogs

617, 855

RELAXATION human pulmonary muscle preparations PG12 and analogs 845

845

651

RELAXIN 16, 16-dimethyl-trans 2-PGE methyl ester serum, early pregnancy 749

739

SELECTIVE SUPERFUSION BIOASSAY leukotrienes 663 prostanoids 663 SYNTHESIS cyclic AMP, bovine luteal cells endogenous prostaglandin 459 gastrointestinal tract, rabbit progesterone, bovine luteal cells PGE allenic analog 169 rat PGI 3 thrgrhboxaneAZ, rat 3 TAURINE PGI synthesis 3 thr&mboxane A2 synthesis

227 459 227

3

THROMBOXANE complement-mediated production. rabbit liver mepacrine 287 THROMBOXANE A2 constriction 777 hemoglobin release 75 mimetics, CTA2 and U46619 75 synthesis 3 vascular, DAHL salt sensitive rats THROMBOXANE A /PGH AGONIST binding to waghed slatelets U46619 789

727

789

THROMBOXANE B antibody-affihity column 149 gas chromatography-mass spectrometry THROMBOXANE B RELEASE fetal placenti, human hypoxia 553

287

149

553

THROMBOXANE SYNTHETASE INHIBITION arachidonic acid metabolism a79 E. Coli endotoxemia a79 furosemide-induced plasma renin activity 275 PGI formation 275 pyr zdoquinazoline thromboxane synthase inhibitor

a79

U46619 binding to washed platelets 789 TXA2/PGH2 agonist VASCULAR RESPONSIVENESS essential fatty deficient diet isolated perfused lungs, rat vascular rings, rat iai

789

181 iai